12 Month Price Forecast For CVM
Distance to CVM Price Forecasts
CVM Price Momentum
๐ค Considering CEL-SCI (CVM)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 9:58 AM UTC
CVM Analyst Ratings & Price Targets
Based on our analysis of 3 Wall Street analysts, CVM has a consensus that is bullish. The median price target is $7.00, with forecasts ranging from $6.20 to $10.00. Currently, there are 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With CVM currently trading at $0.38, the median price forecast suggests a 1,747.5% upside. The most optimistic forecast comes from Tony Butler at EF Hutton, projecting a 2,539.2% upside, while at provides the most conservative target, suggesting a 1,536.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CVM Analyst Consensus
CVM Price Target Range
Latest CVM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CVM.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jul 12, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $10.00 |
Mar 9, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $10.00 |
Feb 17, 2023 | EF Hutton | Tony Butler | Buy | Assumes | $10.00 |
Dec 29, 2022 | EF Hutton | Tim Moore | Buy | Maintains | $16.00 |
Aug 25, 2022 | EF Hutton | Buy | Initiates | $0.00 | |
Apr 7, 2022 | EF Hutton | Buy | Initiates | $0.00 | |
Jan 13, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
Jan 13, 2020 | H.C. Wainwright | Buy | Initiates | $0.00 | |
Feb 20, 2013 | Taglich Brothers | Speculative Buy | Initiates | $0.00 | |
Feb 13, 2013 | Chardan Capital | Buy | Initiates | $0.00 | |
Jan 14, 2013 | Laidlaw & Co. | Buy | Initiates | $0.00 |
Stocks Similar to CEL-SCI Corp
The following stocks are similar to CEL-SCI based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CEL-SCI Corp (CVM) Financial Data
CEL-SCI Corp has a market capitalization of $28.43M with a P/E ratio of -0.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -250.2%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

CEL-SCI Corp (CVM) Company Overview
About CEL-SCI Corp
Develops immune therapies for cancer treatment.
The company focuses on the research and development of immune system therapies, primarily generating revenue through the advancement of its clinical-stage products, particularly the Multikine immunotherapy. CEL-SCI is also developing additional products using its proprietary LEAPS technology, which targets various diseases, thereby expanding its potential market opportunities.
CEL-SCI Corporation has been operational since 1983 and is based in Vienna, Virginia. Its lead product has completed Phase 3 clinical trials, indicating a strong commitment to advancing cancer treatment options. The company is also exploring treatments for autoimmune conditions and has several LEAPS-based candidates in the preclinical stage.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Mr. Geert R. Kersten Esq.
Country
United States
IPO Year
1991
Website
cel-sci.comCEL-SCI Corp (CVM) Latest News & Analysis
CEL-SCI reported fiscal 2024 results and plans to begin a confirmatory study for Multikine, which may establish a new standard of care for head and neck cancer.
CEL-SCI's confirmatory study for Multikine could establish a new treatment standard for head and neck cancer, potentially boosting market value and attracting investor interest.
CEL-SCI Announces Closing of $5 Million Offering
1 month agoCEL-SCI has successfully closed a $5 million offering, as announced in Vienna, Virginia.
CEL-SCI's $5 million offering indicates potential liquidity for growth, impacting stock valuation and investor confidence in the company's future projects.
CEL-SCI Corporation has announced a proposed public offering of common stock.
CEL-SCI's proposed public offering can dilute existing shares and impact stock price, signaling capital needs or growth strategies that may affect investor sentiment and valuation.
CEL-SCI has announced a public offering priced at $5 million.
CEL-SCI's $5 million public offering may dilute existing shares, impacting stock value and investor sentiment. It also signals the company's need for capital, which could affect future growth.
CEL-SCI emphasizes the biological rationale for using Multikine in its Confirmatory Registration Study for head and neck cancer.
Positive developments regarding Multikine's biological rationale may enhance its approval prospects, impacting CEL-SCI's stock price and investor sentiment in the biotech sector.
CEL-SCI and the U.S. FDA have agreed to use the PD-L1 biomarker for selecting head and neck cancer patients in a marketing registration study set to begin in Q1 2025.
FDA agreement on the PD-L1 biomarker for CEL-SCI's Multikine could enhance its market potential in head and neck cancer, impacting future revenue and stock performance.
Frequently Asked Questions About CVM Stock
What is CEL-SCI Corp's (CVM) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, CEL-SCI Corp (CVM) has a median price target of $7.00. The highest price target is $10.00 and the lowest is $6.20.
Is CVM stock a good investment in 2025?
According to current analyst ratings, CVM has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CVM stock?
Wall Street analysts predict CVM stock could reach $7.00 in the next 12 months. This represents a 1,747.5% increase from the current price of $0.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CEL-SCI Corp's business model?
The company focuses on the research and development of immune system therapies, primarily generating revenue through the advancement of its clinical-stage products, particularly the Multikine immunotherapy. CEL-SCI is also developing additional products using its proprietary LEAPS technology, which targets various diseases, thereby expanding its potential market opportunities.
What is the highest forecasted price for CVM CEL-SCI Corp?
The highest price target for CVM is $10.00 from Tony Butler at EF Hutton, which represents a 2,539.2% increase from the current price of $0.38.
What is the lowest forecasted price for CVM CEL-SCI Corp?
The lowest price target for CVM is $6.20 from at , which represents a 1,536.3% increase from the current price of $0.38.
What is the overall CVM consensus from analysts for CEL-SCI Corp?
The overall analyst consensus for CVM is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are CVM stock price projections?
Stock price projections, including those for CEL-SCI Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.